Sexually transmitted infections, sexual life and risk behaviours of people living with schizophrenia: systematic review and meta-analysis

Sexually transmitted infections, sexual life and risk behaviours of people living with schizophrenia: systematic review and meta-analysis Claudia Aymerich, Borja Pedruzo, Gonzalo Salazar de Pablo, Lander Madaria, Javier Goena, Vanessa Sanchez-Gistau, Paolo Fusar-Poli, Philip McGuire, Miguel Ángel González-Torres†and Ana Catalan† Background Sexually transmitted infections (STIs), along with sexual health and behaviour, have received little attention in schizophrenia patients. Aims To systematically review and meta-analytically characterise the prevalence of STIs and sexual risk behaviours among schizophrenia patients. Method Web of Science, PubMed, BIOSIS, KCI-Korean Journal Database, MEDLINE, Russian Science Citation Index, SciELO and Cochrane Central Register were systematically searched from inception to 6 July 2023. Studies reporting on the prevalence or odds ratio of any STI or any outcome related to sexual risk behaviours among schizophrenia samples were included. PRISMA/MOOSE-compliant (CRD42023443602) random-effects meta-analyses were used for the selected outcomes. Q-statistics, I 2 index, sensitivity analyses and meta-regressions were used. Study quality and publication bias were assessed. Results Forty-eight studies (N= 2 459 456) reporting on STI prevalence (including 15 allowing for calculation of an odds ratio) and 33 studies (N= 4255) reporting on sexual risk behaviours were included. Schizophrenia samples showed a high prevalence of STIs and higher risks of HIV (odds ratio = 2.11; 95% CI 1.23–3.63), hepatitis C virus (HCV, odds ratio = 4.54; 95% CI 2.15–961) and hepatitis B virus (HBV; odds ratio = 2.42; 95% CI 1.95–3.01) infections than healthy controls. HIV prevalence was higher in Africa compared with other continents and in in-patient (rather than out-patient) settings. Finally, 37.7% (95% CI 31.5–44.4%) of patients were sexually active; 35.0% (95% CI 6.6–59.3%) reported consistent condom use, and 55.3% (95% CI 25.0–82.4%) maintained unprotected sexual relationships. Conclusions Schizophrenia patients have high prevalence of STIs, with several-fold increased risks of HIV, HBV and HCV infection compared with the general population. Sexual health must be considered as an integral component of care. Keywords Psychotic disorders/schizophrenia; STI; sexual life; contraception; HIV. Copyright and usage © The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/ licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. The World Health Organization defines sexual health as ‘a state of physical, emotional, mental, and social well-being in sexuality’. 1 Sexuality is a natural aspect of human behaviour and a significant factor in quality of life and maintaining healthy relationships. 2 However, for individuals living with schizophrenia, sexual health has received little attention or recognition as a fundamental aspect of their subjective quality of life and associated care. 3 Data suggest that people with schizophrenia have both quantitative and qualitative differences in their sexual lives compared with the general population, 4 identifying this area of health as one with unmet needs, 5 although sexual interest and activity do not disappear after diagnosis. 6,7 Indeed, individuals with schizophrenia are at a higher risk of engaging in risky sexual behaviors, 7 with potentially harmful physical and mental health consequences such as unwanted pregnancies, 8 exposure to interpersonal violence in relationships 9 and increased prevalence of sexually transmitted infections (STIs). 10 The relationship between STIs and schizophrenia is complex and multifactorial, with an increase of risk of STIs due to psychiatric symptoms (e.g. disorganised behaviour leading to hypersexuality 11 or negative symptoms leading to a lack of skills to assertively negotiate safer relationships 12 ). Severe stigmatisation, particularly in romantic relationships, 13 and high rates of comorbidity with other mental disorders and substance use, 14,15 among many other factors, also contribute to this problem. On the other hand, early exposure to certain microorganisms such as hepatitis C virus (HCV) 16 or chlamydia 17 is associated with a higher risk of developing schizophrenia. 18,19 Comorbidity between schizophrenia and viral diseases leads to a poorer prognosis for both conditions. 20 Despite all the above findings, the sexual lives and risky behaviours of individuals living with severe mental health disorders in general, and schizophrenia in particular, continue to be neglected both in clinical practice and research. There is a significant knowledge gap in the available literature, in contrast to other important aspects of quality of life. 4 Considering these complexities, this systematic review and meta-analysis aimed to fill this gap and examine the prevalence of STIs in this population, their increased risk compared with the general population, and the demographic, clinical and methodological factors influencing this risk. Second, we aimed to characterise the sexual risk behaviours associated with schizophrenia. † These two authors have contributed equally and share the senior authorship position. BJPsych Open (2024) 10, e110, 1–11. doi: 10.1192/bjo.2024.49 1 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press Method This study protocol was registered on PROSPERO (registration number: CRD42023443602). The study was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 21 (Supplementary Table 1 available at https://doi.org/10.1192/bjo.2024.49) and MOOSE (MetaAnalyses of Observational Studies in Epidemiology 22 (Supplementary Table 2) checklists, following the EQUATOR reporting guidelines. 23 Search strategy and selection criteria A systematic literature search was carried out dually and independently by two investigators (C.A. and B.P.). The search encompassed the Web of Science database (Clarivate Analytics), including the Web of Science Core Collection, PubMed, the BIOSIS Citation Index, the KCI-Korean Journal Database, MEDLINE, the Russian Science Citation Index, and the SciELO Citation Index, as well as the Cochrane Central Register of Reviews and Ovid/PsycINFO databases, from inception until 6 July 2023. Two separated searches were conducted: one to identify articles containing information on the prevalence and relative risk of sexually transmitted diseases among people with a diagnosis of schizophrenia spectrum disorder, and the other to identify articles reporting on outcomes related to sexual behaviour among the same population. The complete search terms are available in Supplementary Table 3. Articles identified underwent an initial screening of their abstracts by the two reviewers. Subsequently, after exclusion of those that did not meet the inclusion criteria, the full texts of the remaining articles were dually assessed for eligibility and inclusion. Inclusion criteria for the systematic review and meta-analysis were: (a) individual studies with original data; (b) reporting on patients meeting criteria for any schizophrenia spectrum disorder (including schizophrenia, schizophreniphorm disorder, schizoaffective disorder, delusional disorder, and brief psychotic disorder, according to DSM-5-TR 24 or ICD-11 25 criteria); (c) reporting either quantitative data on the prevalence of an STI (including HIV, human papillomavirus, hepatitis B virus (HBV), HCV, Treponema pallidum, Neisseria gonorrhoeae,Mycoplasma genitalium and Chlamydia trachomatis) using a serological, microbiological or clinical diagnosis provided by a healthcare specialist, or either any outcome related to sexual behaviour (a complete list of the sought-out, standardised outcomes is available in Supplementary Table 4); (d) nonoverlapping samples (overlap was ascertained by examining the inclusion dates, the demographics of the population and the country where the study was conducted; the study with the largest sample was selected); and (e) written in the English language. Exclusion criteria were (a) reviews, clinical cases, study protocols or qualitative studies, conferential proceedings, letters and commentaries; (b) reporting on patients with an affective psychotic disorder according to DSM/ICD criteria; 24,25 (c) reporting on a subsample of schizophrenia patients specifically selected for their characteristics or risk of an STI; and (d) written in languages other than English. Data extraction Three reviewers (B.P., L.M. and J.G.) independently conducted data extraction from all the studies included, starting on 20 July 2023. Subsequently, the three databases were cross-checked, and any inconsistencies were resolved through consensus under the supervision of a senior researcher (A.C.). For the included articles, a summary of the selected variables included: first author and year of publication, country and city, sample size, age in years (mean ± s.d.), sex (percentage female), STI diagnostic method, relationship status (percentage in stable relationship), substance use disorder according to any DSM or ICD criteria (excluding nicotine) (%), quality assessment (see below) and key findings. When stratified data were available, data were extracted separately for male and female populations. Risk of bias (quality) assessment Risk of bias was independently assessed by B.P. and C.A. using a modified version of the Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomised studies. This choice was made taking into account the heterogeneity expected in the included studies 26 (Supplementary Table 5). Any discrepancy between the two assessments was resolved through consensus. Strategy for data synthesis First, we provided a systematic synthesis of the findings from the included studies structured around two main topics: the prevalence and relative risk of the examined STIs, and the included sex behaviour outcomes (Table 1 and Supplementary Table 6, respectively). Second, where data allowed, we performed meta-analyses using as primary effect size the prevalence (percentage and standard error, when available) of the STIs. Each STI was separately analysed. Then, for those articles where the prevalence of STIs in a comparison group of healthy controls (defined as people without any mental health disorder) was also available, the odds ratio with a 95% confidence interval was calculated using the number of individuals with any particular STI and samples sizes for each sample, without adjusting by any variable, and then separately metaanalysed for each STI. An odds ratio greater than 1 indicated that the schizophrenia group had a higher risk of presenting with any particular STI than the healthy control group. Separate proportion meta-analyses were also conducted to study the pooled prevalence of each sexual behaviour or risk behaviour when three or more samples were available. The heterogeneity between studies was measured using the Q-statistic, and percentages of overall variability in the estimates of ORs were determined using the I 2 index, classifying the heterogeneity into low (I 2 = 25%), medium (I 2 = 50%) and high (I 2 = 75%). 27 Meta-regressions were performed to study the effects of (a) age, (b) publication year, (c) percentage of females, (d) percentage of patients with substance use disorder, (e) percentage of patients in a stable relationship, and (f) risk of bias (NOS score) on outcomes where seven or more articles provided the data. Sensitivity analyses were performed to determine differences depending on (a) sample continent, (b) sample type (first-episode psychosis, defined as patients presenting with psychosis for fewer than 5 years from the initial onset, 24 versus chronic schizophrenia), and (c) setting (in-patient versus out-patient) with respect to the study outcomes when more than ten articles were available. A random-effects model was used, owing to the expected high heterogeneity. Publication bias was assessed by visual inspection of the funnel plots; when more than ten articles were available, Egger’s test was also performed. All analyses were conducted within R 4.2.2 28 using the metafor package. 29 The significance level was set at P< 0.05, two-sided. Results Sexually transmitted diseases The literature search of electronic databases yielded 1734 citations, which were screened for eligibility; 95 articles underwent fulltext assessment, and 47 were excluded. The final sample for the Aymerich et al 2 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press Table 1 Characteristics of the studies included in the sexually transmitted infections systematic review Study Country STI N, schizophrenia patients (STI) N, healthy controls (STI) Age in years, mean (s.d.) Percentage women Setting Percentage with SUD Percentage in stable relationship NOS Opondo et al, 2017 Botswana HIV 545 (152) –30.3 (3.8) 22% In-patient n.a. 5% 7 Said et al, 2001 Jordan HBV 192 (14) 192 (5) 39.9 (n.a.) 45% In-patient n.a. n.a. 6 Doufik et al, 2022 Morocco HIV 444 (0) –33.5 (9.2) 10% Other n.a. 24% 5 HBV 444 (7) – HCV 444 (4) – T. pallidum 444 (16) – Mona et al, 2022 South Africa HIV 370 (45) –n.a. 30% In-patient n.a. 6% 7 Mwelase et al, 2023 South Africa HIV 294 (62) –n.a. 31% In-patient 53% 58% 8 Lundberg et al, 2013 Uganda HIV 224 (26) 15 108 (1330) n.a. 51% Other n.a. 14% 8 Maling et al, 2011 Uganda HIV 87 (13) –n.a. n.a. In-patient n.a. n.a. 8 Mbewe et al, 2006 Zambia HIV 160 (5) –37.5 (21.4) 28% In-patient 56% n.a. 6 Wang et al, 2016 China HBV 415 (28) 3038 (101) 18.5 (1.6) 48% Other n.a. n.a. 6 Zhan et al, 2018 China T. pallidum 1586 (53) –n.a. n.a. Other n.a. n.a. 8 Zhu et al, 2015 China HBV 1649 (181) –34.0 (n.a.) 54% Other n.a. n.a. 7 Chaudury et al, 1994 India HBV 100 (11) 100 (2) 54.6 (8.4) 0% In-patient n.a. n.a. 4 Imani et al, 2022 Iran HBV 92 (1) –n.a. n.a. Other n.a. n.a. 7 Nakamura et al, 2004 Japan HCV 455 (28) 197 827 (2374) n.a. n.a. In-patient n.a. n.a. 8 Chang et al, 2021 Taiwan HBV 15 914 (465) –40.1 (9.7) n.a. Other n.a. n.a. 9 HCV 15 914 (181) – Chiu et al, 2017 Taiwan HCV 6097 (127) 6097 (85) 43.3 (13.7) 48% Other 2% n.a. 7 Hung et al, 2012 Taiwan HBV 511 (53) –42.5 (10.7) 42% In-patient n.a. n.a. 8 HCV 577 (11) – Hariri et al, 2011 Turkey HIV 88 (0) –34.9 (8.8) 64% Out-patient n.a. n.a. 8 HBV 88 (0) – HCV 88 (0) – De Hert et al, 2009 Belgium HIV 595 (3) –36.7 (11.2) 35% Other n.a. 13% 7 HCV 595 (4) – Fellerhoff et al, 2011 Germany C. trachomatis 72 (2) −n.a. n.a. Other n.a. n.a. 7 Krause et al, 2010 Germany C. trachomatis 31 (8) −n.a. n.a. Other n.a. n.a. 7 Grassi et al, 1999 Italy HIV 33 (1) −35.3 (8.1) 35% Other 43% 15% 6 Cuadrado et al, 2020 Spain HCV 425 (8) −36.5 (n.a.) 47% Other n.a. n.a. 7 González-Torres et al, 2015 Spain HIV 235 (5) −n.a. n.a. In-patient n.a. n.a. 7 Bauer-Staeb, 2017 Sweden HIV 21 232 (44) 6 815 931 (5909) 46.0 (8.1) 50% Other 4% n.a. 8 HBV 21 232 (112) 6 815 931 (112) HCV 21 232 (1194) 6 815 931 (41 600) Jallow et al, 2016 Sweden HIV 10 347 (65) −n.a. 46% Out-patient n.a. n.a. 8 Karabulut et al, 2016 Turkey HIV 489 (0) −42.5 (11.3) 16% Other n.a. n.a. 7 HBV 489 (32) − HCV 489 (1) − Heslin et al, 2022 United Kingdom HIV 8562 (174) −n.a. n.a. Out-patient n.a. n.a. 9 Closson et al, 2019 Canada HIV 6454 (835) 507 670 (12 499) n.a. 41% Other 49% n.a. 8 Sockalingam et al, 2010 Canada HCV 110 (3) −44.7 (10.8) 32% Other 7% n.a. 7 Rodgers-Johnson et al, 1996 Jamaica HIV 201 (5) −n.a. 38% In-patient n.a. 17% 7 Alvarado-Esquivel et al, 2005 Mexico HBV 33 (4) –n.a. n.a. In-patient n.a. n.a. 7 Baillargeon et al, 2008 USA HIV 4736 (173) –n.a. n.a. Other n.a. n.a. 5 Blank et al, 2002 USA HIV 8208 (98) 374 253 (2062) 40.3 (17.6) 47% Other n.a. n.a. 6 Carney et al, 2006 USA HCV 1074 (7) 726 262 (492) 40.2 (11.9) 53% Other 9% n.a. 7 Dinwiddie et al, 2003 USA HCV 153 (14) –n.a. n.a. In-patient n.a. n.a. 7 (Continued) Sexual health of people living with schizophrenia 3 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press systematic review and STI meta-analyses included 48 studies (Supplementary Fig. 1(a)). Twenty-eight studies (58.3%) included data on HIV, 30,57 20 (41.7%) on HCV, 36,40,45,48,50,51,54,55,57,67 14 (29.2%) on HBV, 36,48,50,51,54,57,60,64,68,72 three (8.3%) on C. trachomatis 17,49,73 and three (6.3%) on T. pallidum. 36,48,74 No studies fulfilling our inclusion criteria were found regarding other STIs included in our search. The full sample included 2 459 456 patients with schizophrenia. The mean age of the sample was 50.3 years, ranging from 16 to 73 years (s.d. = 11.9); 21.1% were female, 24.8% were in a stable relationship, and 23.7% presented with a comorbid substance use disorder other than nicotine-related. Among the studies reporting the prevalence of a comorbid substance use disorder, two reported on alcohol and cannabinoids, 30,32 four reported on the use of injectable drugs, 41,51,53,58 four reported on both of these categories, 40,45,49,63 and six did not specify the substance or substances used. 39,43,54,59,62,66 Studies included samples from 24 countries in six continents: 17 (35.4%) from North America, ten (20.8%) from Europe, ten (20.8%) from Asia, eight (16.7%) from Africa, two (4.2%) from Oceania and one (2.1%) from South America. The mean NOS score for the included studies was 6.9 ± 1.2 (Table 2A and Supplementary Table 6). Fifteen of the included studies provided data for a healthy control comparison group, thereby enabling the calculation of an odds ratio. Of these studies, seven included data on HIV, 33,38,39,41,44,45,54 seven on HCV 45,54,61,63,66,67 and four on HBV 54,69,72,75 (Table 2B). HIV The prevalence of HIV among people with schizophrenia was reported in 28 studies, comprising a total sample of 2 421 702 patients. All HIV diagnosis were serological. The pooled prevalence of HIV was 1.67% (95% CI 0.82–3.37%) (Fig. 1). Meta-regressions found a statistically significant higher prevalence of HIV among samples with higher prevalence of substance use disorder (β= 8.079; 95% CI 0.003–4.020) but no statistically significant effect of age, sex, relationship status, risk of bias or publication year (Supplementary Table 7). Prevalence of HIV was significantly higher in samples from Africa (7.32%; 95% CI 1.51–28.94%) and in in-patient settings (5.94%; 95% CI 1.78–18.04%) when compared with other continents or with out-patient settings (Supplementary Table 9). No publication bias was identified by visual inspection of the funnel plot (Supplementary Fig. 3(a)) or by Egger’s test (P= 0.48). Seven of these studies also included the prevalence of HIV in a healthy control comparison sample (total sample: 346 362 patients with schizophrenia and 11 870 350 healthy controls), allowing for an odds ratio calculation. The odds ratio for HIV infection was 2.11 (95% CI 1.23–3.63, P< 0.01), implying a statistically significant higher risk of HIV infection in the schizophrenia sample (Fig. 2). Meta-regressions revealed no statistically significant effect of risk of bias or publication year. The funnel plot did not suggest the presence of publication bias (Supplementary Fig. 3(b)). Hepatitis C virus The prevalence of HCV among the schizophrenia sample was reported in 20 studies (total sample: 146 326 patients). All diagnosis were serological. The pooled prevalence of HCV was 2.82% (95% CI 1.51–5.20%) (Supplementary Fig. 2(a)). Meta-regressions found a statistically significant higher prevalence of HCV prevalence in older samples (β= 0.143; 95% CI 0.090–0.196) and samples with higher prevalence of substance use disorder (β= 4.201; 95% CI 0.692–7.710) and in older articles (publication year β=−0.097; 95% CI −0.187 to −0.007) (Supplementary Table 8). No effect of Table 1 (Continued) Study Country STI N, schizophrenia patients (STI) N, healthy controls (STI) Age in years, mean (s.d.) Percentage women Setting Percentage with SUD Percentage in stable relationship NOS Doyle et al, 1997 USA HIV 138 (0) –32.0 (13.7) n.a. In-patient 27% n.a. 5 Freudenreich et al, 2007 USA HCV 98 (8) –44.7 (n.a.) 25% Out-patient n.a. n.a. 6 Fuller et al, 2011 USA HCV 6521 (1076) 6521 (124) 57.2 (n.a.) 6% Other 65% n.a. 8 Hart et al, 1999 USA HIV 38 (2) 16 (0) n.a. n.a. Other n.a. n.a. 4 Himelhoch et al, 2007 USA HIV 89 189 (858) 67 965 (346) 55.5 (11.9) 5% Other 25% 25% 7 HCV 89 189 (6287) 67 965 (1708) Huckans et al, 2006 USA HCV 2207 (219) 73 687 (3888) n.a. n.a. Other n.a. n.a. 6 Prince et al, 2012 USA HIV 221 017 (1413) 4 089 407 (24 607) n.a. n.a. Other n.a. n.a. 8 Rosengerg et al, 2005 USA HIV 495 (18) –n.a. 32% Other 29% n.a. 7 HCV 495 (96) – Walkup et al, 2010 USA HIV 2 047 199 (37 054) –n.a. n.a. Other n.a. n.a. 6 Brown et al, 2021 Australia HIV 69 (1) –19.6 (10.8) 42% Other n.a. 10% 9 C. trachomatis 69 (5) – Williams et al, 2020 Australia HIV 97 (0) –46.0 (n.a.) 40% Out-patient n.a. n.a. 6 HBV 97 (0) – HCV 97 (7) – Santos da Silva et al, 2019 Brazil HIV 66 (0) –n.a. n.a. Out-patient n.a. n.a. 8 HBV 66 (1) – HCV 66 (0) – T. pallidum 66 (0) – STI, sexually transmitted disease; SUD, substance use disorder; NOS, Newcastle–Ottawa Scale; HBV, hepatitis B virus; HCV, hepatitis C virus. Aymerich et al 4 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press setting was detected in the sensitivity analyses (Supplementary Table 10), and no publication bias was identified (Supplementary Fig. 3(c)). Seven of these studies also included the prevalence of HCV for a healthy control comparison group (total sample: 126 775 patients with schizophrenia and 7 894 290 healthy controls), allowing for Table 2A Prevalence of sexually transmitted infections STI Number of studies Sample size Prevalence 95% CI Heterogeneity I 2 (%) P HIV 28 2 421 702 0.0167 0.0082–0.0337 99.6 <0.01 HCV 20 146 326 0.0282 0.0151–0.0520 99.0 <0.01 HBV 14 41 322 0.0326 0.0157–0.0664 98.4 <0.01 C. trachomatis 3 172 0.0850 0.0069–0.5540 82.4 <0.01 T. pallidum 3 2096 0.0329 0.0197–0.0545 0.00 0.96 STI, sexually transmitted infection; HCV, hepatitis C virus; HBV, hepatitis B virus. Table 2B Odds ratio for the risk of each sexually transmitted infection among schizophrenia samples compared with healthy control samples STI Number of studies Schizophrenia patient sample Healthy control sample Odds ratio 95% CI P-value Heterogeneity I 2 (%) P HIV 7 346 362 11 870 350 2.11 1.23–3.63 0.01 99.5 0.00 HCV 20 126 775 7 894 290 4.54 2.15–9.61 0.00 99.5 0.00 HBV 4 21 939 6 819 261 2.42 1.95–3.01 0.00 0.00 0.59 STI, sexually transmitted infection; HCV, hepatitis C virus; HBV, hepatitis B virus. Study Events Random-effects model 2 421 702 0.0167 0.0082–0.0337 Total Proportion 95% CI Karabulut, 2016 0 489 0.0000 0.0000–0.0075 0.0000 0.0021 0.0000–0.0083 0.0015–0.0028 0.0000 0.0000–0.0264 0.0050 0.0010–0.0147 0.0000 0.0000–0.0373 0.0000 0.0000–0.0411 0.0062 0.0048–0.0079 0.0064 0.0061–0.0067 0.0000 0.0000–0.0544 0.0096 0.0090–0.0103 0.0119 0.0097–0.0145 0.0145 0.0004–0.0781 0.0181 0.0179–0.0183 0.0203 0.0174–0.0235 0.0213 0.0069–0.0490 0.0249 0.0081–0.0571 0.0303 0.0008–0.1576 0.0312 0.0102–0.0714 0.0364 0.0217–0.0569 0.0365 0.0314–0.0423 0.0526 0.0064–0.1775 0.1161 0.0772–0.1654 0.1216 0.0901–0.1593 0.1294 0.1213–0.1378 0.1494 0.0820–0.2420 0.2109 0.1657–0.2620 0.2789 0.2416–0.3186 444 21 232 138 595 97 88 10 437 221 017 66 89 189 8208 69 2 047 199 8562 235 201 33 160 495 4736 38 224 370 6454 87 294 545 0 44 0 3 0 0 65 1413 0 858 98 1 37 054 174 5 5 1 5 18 173 2 26 45 835 13 62 152 0 0.05 0.1 0.15 0.2 0.25 0.3 Doufik, 2022 Bauer-Staeb, 2017 Doyle, 1997 DeHert, 2009 Williams, 2020 Hariri, 2011 Jallow, 2016 Prince, 2012 SantosDaSilva, 2021 Himelhoch, 2007 Blank, 2002 Brown, 2021 Walkup, 2010 Heslin, 2022 Gonzalez-Torres, 2015 Rodgers-Johnson, 1996 Grassi, 1999 Mbewe, 2006 Rosengerg, 2005 Baillargeon, 2008 Hart, 1999 Lundberg, 2013 Mona, 2022 Closson, 2019 Maling, 2011 Mwelase, 2023 Opondo, 2017 Heterogeneity: I2 = 100%, τ2 = 2.8446, P = 0 Fig. 1 Forest plot of HIV prevalence. Sexual health of people living with schizophrenia 5 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press an odds ratio calculation. The odds ratio for HCV infection was 4.54 (95% CI 2.15–9.61, P< 0.01), implying a statistically significant higher risk of HCV infection in the schizophrenia sample (Supplementary Fig. 2(b)). Meta-regressions revealed no statistically significant effect of risk of bias or publication year, and the funnel plot did not suggest the presence of publication bias (Supplementary Fig. 3(d)). Hepatitis B virus The prevalence of HBV among people with schizophrenia was reported in 14 studies, comprising a total sample of 41 322 patients. All diagnosis were serological. The pooled prevalence of HBV was 3.26% (95% CI 1.57–6.64%) (forest plot available in Supplementary Fig. 2(c)). Meta-regressions found a statistically significant higher prevalence of HBV prevalence in older articles (publication year β=−0.082; 95% CI −0.157 to −0.007) (Supplementary Table 8), and sensitivity analyses found a greater prevalence of HBV among in-patient samples (9.81%; 95% CI 6.99–13.60%) compared with out-patient or mixed samples (Supplementary Table 10). No publication bias was identified (Supplementary Fig. 3(e)). Four of these studies also included the prevalence of HBV for a healthy control comparison sample (total sample: 21 939 patients with schizophrenia and 6 819 261 healthy controls), allowing for an odds ratio calculation. The odds ratio for HBV infection was 2.42 (95% CI 1.95–3.01, P< 0.01), implying a statistically significant higher risk of HBV infection in the schizophrenia sample (Supplementary Fig. 2(d)). The funnel plot did not suggest the presence of publication bias (Supplementary Fig. 3(f)). Not enough data were available to perform any meta-regression or sensitivity analysis. C. trachomatis The prevalence of C. trachomatis in the schizophrenia sample was reported in three studies (total sample: 172 patients). One article provided clinical diagnosis by the patients’general practitioners, 49 another reported serological diagnosis 73 and the third used molecular diagnosis through DNA polymerase chain reaction. 17 The pooled prevalence of chlamydia was 8.50% (95% CI 0.69–55.40%) (Supplementary Fig. 2(e)). Not enough data were available to perform any meta-regression or sensitivity analysis, or to calculate an odds ratio for C. trachomatis comparing a schizophrenia sample with a healthy control comparison sample. T. pallidum The prevalence of T. pallidum in the schizophrenia sample was reported in three studies (total sample: 2096 patients). All diagnoses were serological. The pooled prevalence of T. pallidum was 3.29% (95% CI 1.97–5.45%) (Supplementary Fig. 2(f)). Not enough data were available to perform any meta-regression or sensitivity analysis, or to calculate an OR for T. pallidum comparing a schizophrenia sample with a healthy control comparison sample. Sexual behaviour The literature search of electronic databases yielded 789 citations, which were screened for eligibility; full texts of 344 articles were assessed, and 311 articles were excluded. The final sample for the systematic review and meta-analyses included 33 studies (Supplementary Fig. 1(b)). The full sample comprised 4255 patients with schizophrenia. The mean age of the sample was 38.0 years, ranging from 16 to 65 years (s.d. = 8.02); 51.2% were female, 33.72% declared themselves to be in a stable relationship, and the mean duration of illness was 11.9 years (s.d. = 7.4). Studies included samples from 14 countries in five continents. The mean age at first sexual relationship was 18.15 years. The mean NOS score of the included studies was 6.7 ± 1.2 (Table 2). A detailed description of the meta-analytical results can be found in Table 2; 37.77% (95% CI 18.93–61.22%) considered themselves to be in a stable relationship. 49,50,53,76,91 59.66% (95% CI 43.57–73.91%) reported being interested in sexual relationships with others 4,76,77 and 53.71% (42.85–64.22%) were satisfied with their sex life. 77,85,92 Whereas 74.10% (95% CI 53.20–87.89%) had had sexual relationships with another person at least once in their lifetime, 37,49,53,77,79,81,93 only 37.72% (95% CI 31.52–44.35%) were sexually active (defined in most cases as sexual intercourse at least once over the previous 12 months). 50,53,77,79,84,85,92,94,98 Among those who were sexually active, 35.37% (95% CI 15.56–61.92%) reported having multiple partners, 50,53,83,84,87,96 30.95% (95% CI 11.88–59.84%) had paid for sexual relationships, 50,53,92 and 13.38% (95% CI 5.02–31.09%) reported having had relationships in exchange for goods or money. 50,83,87 Only 34.98% (95% CI 16.58–59.29%) reported consistent use of a condom in their relationships, 37,49,53,80,83,96 whereas 55.28% (95% CI 24.59–82.41%) reported having unprotected sexual relationships, 49,50,80,87,98,99 and 28.72% (95% CI 8.38–63.99%) of patients had experienced an unplanned pregnancy on the part of themselves or their partners 49,50,92,100,101 (Table 3A and Supplementary Fig. 2(g,i)). Metaregressions and sensitivity analyses revealed no statistically significant differences regarding age, sex, risk of bias, publication year, continent or setting for any of the studied outcomes (Supplementary Tables 8 and 10, respectively). The funnel plots did not suggest the presence of publication bias for any of the outcomes (Supplementary Fig. 3). Prince, 2012 1.06 16.9% 15.0% 16.8% 16.4% 2.0% 15.9% 16.9% 1.01–1.12 0.90–2.06 1.67–2.15 1.78–2.67 0.10–49.75 1.78–3.22 5.46–6.34 1.36 1.90 2.18 2.26 2.39 5.89 0.1 0.5 12 10 Lundberg, 2013 Himelhoch, 2007 Blank, 2002 Hart, 1999 Bauer-Staeb, 2017 Closson, 2019 Heterogeneity: I2 = 100%, τ2 = 0.3414, P < 0.01 Study Random-effects model Experimental 1413 26 858 98 2 44 835 221 017 224 89 189 8208 38 21 232 6454 Events Total 346 362 11 870 350 24 607 1330 346 2062 0 5909 12 499 4 089 407 15 108 67 965 374 253 16 6 815 931 507 670 Events Total Odds ratio Odds ratio 2.11 100.0%1.32–3.38 95% CI Weight Control Fig. 2 Forest plot of HIV infection odds ratios. An odds ratio greater than 1 implies that theschizophrenia population has greater risk of the infection. Aymerich et al 6 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press When compared with healthy controls, patients with schizophrenia were significantly less likely to be in a stable relationship (k=6, odds ratio = 0.18, 95% CI 0.07–0.45, P< 0.01) 49,50,78,79,84,89 or to be sexually active (k= 4, odds ratio 0.19, 95% CI 0.13–0.29, P< 0.01) 50,79,84,92 (Tables 2B and 3B, and Supplementary Fig. 2(h, j)). Discussion To the best of our knowledge, this is the first systematic review and meta-analysis to comprehensively assess the prevalence and odds ratios of STIs among people living with schizophrenia, along with their sexual risk behaviours. Several important findings have been made. First, a high prevalence of STIs was noted. The pooled HIV prevalence was 1.67% (with an odds ratio of 2.11 compared with the general population), whereas for HCV and HBV, positivity prevalence reached 2.82 and 3.26%, with ORs of 4.54 and 2.42, respectively. A high prevalence was also been found for less-studied STIs such as T. pallidum (3.3%) and C. trachomatis (8.5%). It is important to highlight that the included studies were cross-sectional, so it can be anticipated that the proportion of individuals with schizophrenia who develop an STI over the course of their lifetime will be substantially higher than reported here. This is in line with previous findings in literature, from systematic reviews 102 and large cohort studies. 10,103 Positive symptoms are associated with disorganised behaviour, substance use (including injection drug use, another major source of contagion for the studied viruses) and hypersexuality in some cases. 87,104 In our meta-analysis, HIV prevalence was substantially higher in samples with higher substance use disorder comorbidity and in samples from Africa, at 7.32%. A previous meta-analysis examining the prevalence of HIV seropositivity among patients with first-episode psychosis patients in the African continent found an even greater pooled prevalence of 26%, which they hypothetically linked to longer duration of untreated schizophrenia, low access to health services and high prevalence of infection in the continent. 105 On the other hand, and more encouragingly, the prevalence of HBV and HCV appears to be lower according to more recently published articles (and in the case of HCV, for samples with younger mean age). Global trends for hepatitis B and C have shown a positive evolution over the last decades, 106 especially with the appearance of direct-acting antiviral treatments for HCV. 107 This has been especially notorious in some correctional institutions, 108 where patients with severe mental health disorders are overrepresented. 109 On the other hand, another important finding of our study was that individuals with schizophrenia were significantly less likely to be in a stable relationship (odds ratio = 0.18) or engage in sexual activity with other people (odds ratio = 0.19) compared with healthy controls. This is consistent with previous findings in the literature, with studies reporting both lower rates of marriage and higher rates of divorce among people with schizophrenia. 110 Furthermore, the overall pooled prevalence of patients in our study who declared themselves to be sexually active was under 40%. This could be attributed to several factors. Positive symptoms such as sex-related delusions and hallucinations can have a negative impact on relationships and sexual life, 111 whereas negative symptoms are associated with sexual dysfunction and deficits in sexual interest and activity. 76 In our meta-analysis, 59.6% of patients (pooled prevalence) reported being interested in maintaining sexual intercourse with other people. Bianco et al reported a bimodal distribution of sexual interest among adults with schizophrenia, with most patients reporting either no problem with sexual interest or severe impairment in that area. 76 Even when sexual interest is present, sexual dysfunction is a frequent sideeffect associated with the use of antipsychotic medications, occurring both directly through elevated prolactin due to blockade of dopamine D2 receptors 112 and indirectly through other adverse effects such as metabolic syndrome and obesity. 113 Other sources of sexual dysfunction may include concomitant use of antidepressants and anxiolytics, comorbidity with other mental health and substance use disorders 114 and, in more severely affected populations, the closed management model of most psychiatric inpatient units, which leads to a lack of privacy and limits the Table 3A Prevalence of each of the studied sexual and risk behaviours Number of studies Sample size Prevalence 95% CI Heterogeneity I 2 (%) P Stable relationship (%) 20 2127 0.3777 0.1893–0.6122 93.4 <0.01 Lifetime sexual relationship (%) 7 881 0.7410 0.5320–0.8780 91.9 <0.01 Satisfaction with sex life (%) 3 391 0.5371 0.4285–0.6422 49.7 <0.01 Interest in sexual relationship (%) 3 576 0.5966 0.4357–0.7391 70.8 0.03 Sexually active (%) 16 2292 0.3772 0.3152–0.4435 85.9 <0.01 Among sexually active people with schizophrenia Prostitution use (%) 3 223 0.3095 0.1188–0.5984 80.8 0.01 Prostitution work (%) 3 612 0.1338 0.0502–0.3109 77.3 0.01 Consistent use of condom (%) 6 577 0.3498 0.1658–0.5929 93.5 <0.01 Hormonal contraception (%) 3 154 0.1297 0.0017–0.9300 94.5 <0.01 Unprotected sexual relationship (%) 6 937 0.5528 0.2459–0.8241 97.9 <0.01 Unplanned pregnancy (%) 5 286 0.2872 0.0838–0.6399 92.0 <0.01 Multiple partners (%) 6 861 0.3537 0.1556–0.6192 97.0 <0.01 Table 3B Odds ratio for the risk of being in a stable relationship and being sexually active among schizophrenia samples compared with healthy controls Number of studies Schizophrenia patient sample Healthy control sample Odds ratio 95% CI P-value Heterogeneity I 2 (%) P Stable relationship (%) 6 489 518 0.18 0.07–0.45 0.00* 86.5 0.00 Sexually active (%) 4 285 317 0.19 0.13–0.29 0.00* 27.2 0.00 Sexual health of people living with schizophrenia 7 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press chance of having sexual activity. 5 It is important to address this, as a satisfactory romantic and sexual life has proven to be beneficial for the recovery of people with schizophrenia, increasing selfconfidence, treatment compliance and even overall survival. 5,115 Among those who were sexually active, a great prevalence of risk behaviours was found. Only 34.9 and 12.9% of patients with schizophrenia reported consistently using condoms or hormonal contraception in their sexual relationships, whereas 55.3% of the pooled sample regularly had unprotected intercourse. Moreover, 35.4% of patients reported having multiple concurrent sexual partners, and 28.7% had experienced an unwanted pregnancy either themselves or in their partners. This pattern of concerning sexual behaviours among people living with schizophrenia has been described in previous studies, with a prevalence of risky practices of up to 83%. 83,87 It is important to note that a similar behavioural pattern has been identified among people who have suffered traumatic experiences, particularly sexual trauma, with a higher risk of engaging in risky sexual behaviours such as compulsive sexual behaviour and unprotected sexual intercourse. 116,117 Considering that sexual traumatic history is greatly overrepresented among schizophrenia samples, 118 future research should focus on exploring whether the presence of traumatic history could be a major mediating factor in this population. Our findings pose significant implications for the understanding and care of individuals living with schizophrenia. It is essential to note that most of the studies included in our analyses involved samples that had undergone STI screening for research purposes. This hardly reflects the clinical reality of many centres, where routine screening is not commonly performed in patients with severe mental disorders. Tailored sex education and preventive measures (including regular screening for STIs) are essential for all members of society, and people with schizophrenia are no exception. Interventions targeted at individuals with severe mental health disorders must be put in place to reduce the burden associated with STIs and other adverse consequences of risky sexual behaviours. Limitations The findings of this study should be interpreted considering certain limitations, primarily the significant heterogeneity detected in most of the studied outcomes. Although high heterogeneity is expected in proportional meta-analyses, 119 samples included in this work were heterogeneous in terms of their geographic origin, severity and characteristics, which on the other hand allows for better generalisation of our results. Owing to a lack of data, some potentially moderating factors such as religion, 120 antipsychotic treatment 121 or access to sexual health services 122 were not analysed. Furthermore, it was not possible to stratify the studied outcomes by sex, even though significant gender-related differences may exist. 123 Another crucial determinant for the transmission of the infections studied is the use of injectable drugs. Although we addressed the effect of a comorbid substance use disorder on the prevalence of STIs through meta-regressions, unfortunately there were insufficient data to stratify the effect of each substance, or the injection route. In the case of sexual behaviour outcomes, most of the data in the original studies were obtained through self-report, which can be potentially subject to social desirability bias; this has proven to be particularly problematic in studies on this topic. 124 Although it remains unclear whether this bias differentially affects populations with severe mental health disorders, it should be considered in future research. Finally, most of the studies included in this analysis were cross-sectional in nature. Longitudinal research is needed to better understand the temporal dynamics of sexual behaviour and STI risk in individuals with schizophrenia. Future implications Patients with schizophrenia exhibit a high prevalence of STIs, having several-fold increased risks of HIV, HBV and HCV infection compared with the general population. Although individuals in this population are significantly less likely to be in a stable relationship or engage in sexual activity, they show extremely high prevalence of risky sexual behaviours, engaging in unprotected sexual relationships. These findings highlight the need to incorporate sexual health into the overall care framework for patients with schizophrenia, with the aim of preventing and treating sexually transmitted diseases. Claudia Aymerich , MD, Psychiatry Department, Basurto University Hospital, Osakidetza, Basque Health Service, Bilbao, Spain; Biobizkaia Health Research Institute, OSI Bilbao-Basurto, Bilbao, Spain; Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain; and Neuroscience Department, University of the Basque Country, Leioa, Spain; Borja Pedruzo, MD, Psychiatry Department, Basurto University Hospital, Osakidetza, Basque Health Service, Bilbao, Spain; Gonzalo Salazar de Pablo , PhD, Child and Adolescent Mental Health Services, South London and the Maudsley NHS Foundation Trust, London, UK; Institute of Psychiatry and Mental Health. Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERSAM, Madrid, Spain; and Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, London, UK; Lander Madaria, MD, Psychiatry Department, Basurto University Hospital, Osakidetza, Basque Health Service, Bilbao, Spain; and Biobizkaia Health Research Institute, OSI Bilbao-Basurto, Bilbao, Spain; Javier Goena, MD, Psychiatry Department, Basurto University Hospital, Osakidetza, Basque Health Service, Bilbao, Spain; Vanessa Sanchez-Gistau, PhD, Early Intervention in Psychosis Service, Hospital Universitari Institut Pere Mata, IISPV-CERCA, CIBERSAM, ISCIII, Universitat Rovira i Virgili, Reus, Spain; Paolo Fusar-Poli, PhD, Early Psychosis: Interventions and ClinicalDetection Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; OASIS Service, South London and Maudsley National Health Service Foundation Trust, London, UK; and National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK; Philip McGuire , FMedSci, Department of Psychiatry, University of Oxford, Oxford, UK; and NIHR Oxford Health Biomedical Research Centre, Oxford, UK; Miguel Ángel González-Torres, PhD, Psychiatry Department, Basurto University Hospital, Osakidetza, Basque Health Service, Bilbao, Spain; Biobizkaia Health Research Institute, OSI Bilbao-Basurto, Bilbao, Spain; CIBERSAM, Madrid, Spain; and Neuroscience Department, University of the Basque Country, Leioa, Spain; Ana Catalan, PhD, Psychiatry Department, Basurto University Hospital, Osakidetza, Basque Health Service, Bilbao, Spain; Biobizkaia Health Research Institute, OSI Bilbao-Basurto, Bilbao, Spain; CIBERSAM, Madrid, Spain; Neuroscience Department, University of the Basque Country, Leioa, Spain; Early Psychosis: Interventions and Clinical-Detection Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; and Department of Psychiatry, University of Oxford, Oxford, UK Correspondence: Claudia Aymerich. Email: [email protected] First received 10 Nov 2023, final revision 28 Feb 2024, accepted 5 Mar 2024 Supplementary material Supplementary material is available online at https://doi.org/10.1192/bjo.2024.49. Data availability The data that support the findings of this study are available from the corresponding author, C.A., on reasonable request. Author contributions C.A.: conceptualisation, methodology, project administration, writing –original draft; B.P.: conceptualisation, data curation, writing –original draft; G.S.d.P.: writing –review and editing, formal analysis; L.M.: data curation, writing –review and editing; J.G.: data curation, writing – review and editing; V.S.-G.: conceptualisation, writing –review and editing; P.F.-P.: conceptualisation, writing –review and editing, supervision; P.M.: conceptualisation, writing –review and editing; M.A.G.-T.: conceptualisation, writing –review and editing; A.C.: supervision, formal analysis, validation, writing –review and editing. Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Declaration of interests C.A. has received personal fees or grants from Janssen Cilag and Neuraxpharm outside the current work. G.S.d.P. has received personal fees or grants from Janssen Cilag and Menarini. A.C. has received personal fees or grants from Janssen Cilag, ROVI and Lundbeck outside the current work. Aymerich et al 8 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press References 1World Health Organization. Sexual and Reproductive Health and Research. WHO, n.d. (https://www.who.int/teams/sexual-and-reproductive-health-andresearch-(srh)/overview). 2van Lankveld J, Jacobs N, Thewissen V, Dewitte M, Verboon P. The associations of intimacy and sexuality in daily life: temporal dynamics and gender effects within romantic relationships. J Soc Pers Relat 2018; 35: 557–76. 3Fusar-Poli P, Estradé A, Stanghellini G, Venables J, Onwumere J, Messas G, et al. The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics. World Psychiatry 2022; 21: 168–88. 4de Jager J, McCann E. Psychosis as a barrier to the expression of sexuality and intimacy: an environmental risk? Schizophr Bull 2017; 43: 236–9. 5Yang J, Yu K, Wang X, Wang Y, Zhang C, Ma R, et al. Sexual needs of people with schizophrenia: a descriptive phenomenological study. BMC Psychiatry 2023; 23: 147. 6Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr Bull 2004; 30: 767–79. 7Higgins A, Barker P, Begley CM. Sexual health education for people with mental health problems: what can we learn from the literature? J Psychiatr Ment Health Nurs 2006; 13: 687–97. 8Posada Correa AM, Andrade Carrillo RA, Suarez Vega DC, Gómez Cano S, Agudelo Arango LG, Tabares Builes LF, et al. Sexual and reproductive health in patients with schizophrenia and bipolar disorder. Rev Colomb Psiquiatr 2020; 49:15–22. 9Khalifeh H, Oram S, Osborn D, Howard LM, Johnson S. Recent physical and sexual violence against adults with severe mental illness: a systematic review and meta-analysis. Int Rev Psychiatry 2016; 28: 433–51. 10 Liang C, Bai Y, Hsu J, Huang K, Ko N, Chu H, et al. The risk of sexually transmitted infections following first-episode schizophrenia among adolescents and young adults: a cohort study of 220 545 subjects. Schizophr Bull 2020; 46: 795–803. 11 Ciocca G, Jannini TB, Ribolsi M, Rossi R, Niolu C, Siracusano A, et al. Sexuality in ultra-high risk for psychosis and first-episode psychosis. A systematic review of literature. Front Psychiatry 2021; 12: 750033. 12 Brüne M, Schaub D, Juckel G, Langdon R. Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology. Psychiatry Res 2011; 190:9–17. 13 Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet 2009; 373: 408–15. 14 Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr Res 2018; 194:78–85. 15 Lu C, Jin D, Palmer N, Fox K, Kohane IS, Smoller JW, et al. Large-scale realworld data analysis identifies comorbidity patterns in schizophrenia. Trans Psychiatry 2022; 12: 154. 16 Cheng J, Hu J, Chang M, Lin M, Ku H, Chien R, et al. Hepatitis C–associated lateonset schizophrenia: a nationwide, population-based cohort study. J Psychiatry Neurosci 2021; 46: E583–91. 17 Fellerhoff B, Laumbacher B, Mueller N, Gu S, Wank R. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol Psychiatry 2007; 12: 264–72. 18 Dragioti E, Radua J, Solmi M, Arango C, Oliver D, Cortese S, et al. Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. Mol Psychiatry 2022; 27: 3510–9. 19 Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phiphopthatsanee N, Amir T, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018; 17:49–66. 20 Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005; 66(Suppl 6): 27–33. 21 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. 22 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Metaanalysis Of Observational Studies in Epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12. 23 Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: reporting guidelines for health research. Lancet 2008; 371: 1149–50. 24 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. APA, 2022. 25 World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). WHO, 2021. 26 Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, 2012 (https:// www.ohri.ca/programs/clinical_epidemiology/oxford.asp). 27 Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007; 335: 914. 28 R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, 2021. 29 Viechtbauer W. Package ‘Metafor’.The Comprehensive R Archive Network, 2015. 30 Mbewe E, Haworth A, Welham J, Mubanga D, Chazulwa R, Zulu MM, et al. Clinical and demographic features of treated first-episode psychotic disorders: a Zambian study. Schizophr Res 2006; 86: 202. 31 Opondo PR, Ho-Foster AR, Ayugi J, Hatitchki B, Pumar M, Bilker WB, et al. HIV prevalence among hospitalized patients at the main psychiatric referral hospital in Botswana. AIDS Behav 2018; 22: 1503–16. 32 Mwelase MP, Ntlantsana V, Tomita A, Chiliza B, Paruk S. HIV prevalence and access to HIV testing and care in patients with psychosis in South Africa. S Afr J Psychiatr 2023; 29: 1918. 33 Lundberg P, Nakasujja N, Musisi S, Thorson AE, Cantor-Graae E, Allebeck P. HIV prevalence in persons with severe mental illness in Uganda: a crosssectional hospital-based study. Int J Ment Health Syst 2013; 7: 20. 34 Maling S, Todd J, Van der Paal L, Grosskurth H, Kinyanda E. HIV-1 seroprevalence and risk factors for HIV infection among first-time psychiatric admissions in Uganda. AIDS Care 2011; 23: 171. 35 Mona K, Ntlantsana V, Tomita AM, Paruk S. Prevalence of cannabis use in people with psychosis in KwaZulu-natal, South Africa. S Afr J Psychiatr 2022; 28: 1927. 36 Doufik J, Zemmama H, Bouri S, Rabhi S, Boujraf S, Aalouane R, et al. Prevalence of sexually transmitted infections in patients with schizophrenia in Morocco. Infect Dis Now 2022; 52: 304. 37 Gonzalez-Torres MA, Salazar MA, Inchausti L, Ibañez B, Pastor J, Gonzalez G, et al. Lifetime sexual behavior of psychiatric inpatients. JSexMed2010; 7: 3045. 38 Hart DJ, Heath RG, Sautter FJ, Schwartz BD, Garry RF, Choi B, et al. Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Biol Psychiatry 1999; 45: 704. 39 Blank MB, Mandell DS, Aiken L, Hadley TR. Co-occurrence of HIV and serious mental illness among medicaid recipients. Psychiatr Serv 2002; 53: 868. 40 Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS 2005; 19(Suppl 3): S26–33. 41 Closson K, McLinden T, Patterson TL, Eyawo O, Kibel M, Card KG, et al. HIV, schizophrenia, and all-cause mortality: a population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. Schizophr Res 2019; 209: 198–205. 42 Baillargeon JG, Paar DP, Wu H, Giordano TP, Murray O, Raimer BG, et al. Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. AIDS Care 2008; 20: 124. 43 Rodgers-Johnson PE, Hickling FW, Irons A, Johnson BK, Irons-Morgan M, Stone GA, et al. Retroviruses and schizophrenia in Jamaica. Mol Chem Neuropathol 1996; 28: 237. 44 Prince JD, Walkup J, Akincigil A, Amin S, Crystal S. Serious mental illness and risk of New HIV/AIDS diagnoses: an analysis of medicaid beneficiaries in eight states. Psychiatr Serv 2012; 63: 1032. 45 Himelhoch S, Mccarthy JF, Ganoczy D, Medoff D, Kilbourne A, Goldberg R, et al. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics 2009; 50: 30. 46 Doyle ME, Labbate LA. Incidence of HIV infection among patients with newonset psychosis. Psychiatr Serv 1997; 48: 237. 47 Walkup J, Akincigil A, Amin S, Hoover D, Siegel M, Crystal S. Prevalence of diagnosed HIV disease among medicaid beneficiaries with schizophrenia in U.S. Metropolitan areas. J Nerv Ment Dis 2010; 198: 682. 48 Santos da Silva AS, Santos Costa FJL, Câmara JT, Das Neves FM, De Assis JT. Disease prevalence in infectious care center of users of psychosocial caxiasMA [Prevalência de doenças infecciosas em usuários de centro de atenção psicossocial de caxias-MA]. Revista de Pesquisa 2018; 10: 137. 49 Brown E, Castagnini E, Langstone A, Mifsud N, Gao C, McGorry P, et al. Highrisk sexual behaviours in young people experiencing a first episode of psychosis. Early Interv Psychiatry 2023; 17: 159. 50 Hariri AG, Karadag F, Gokalp P, Essizoglu A. Risky sexual behavior among patients in Turkey with bipolar disorder, schizophrenia, and heroin addiction. J Sex Med 2011; 8: 2284. Sexual health of people living with schizophrenia 9 https://doi.org/10.1192/bjo.2024.49 Published online by Cambridge University Press